Zai Lab Ltd
HKEX:9688

Watchlist Manager
Zai Lab Ltd Logo
Zai Lab Ltd
HKEX:9688
Watchlist
Price: 14.8 HKD 2.78% Market Closed
Market Cap: 16.6B HKD

Gross Margin
Zai Lab Ltd

62.5%
Current
64%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
62.5%
=
Gross Profit
267.2m
/
Revenue
427.8m

Gross Margin Across Competitors

No Stocks Found

Zai Lab Ltd
Glance View

Market Cap
16.3B HKD
Industry
Biotechnology

Zai Lab Ltd. is an innovative player in the biotech and pharmaceutical landscape, emerging from China with ambitions that stretch globally. Founded in 2013, the company has quickly built a robust portfolio, focusing on oncology, autoimmune disorders, infectious diseases, and neuroscience. Zai Lab has established itself with a hybrid business model that intertwines the agility of a biotech startup with the strategic partnerships of a mature pharmaceutical company. This approach has allowed it to localize and expedite the development of cutting-edge therapeutics for the Chinese market while simultaneously building a presence in international markets. What sets Zai Lab apart is its keen ability to in-license late-stage pharmaceutical assets from global partners, significantly cutting down on the time and resources typically required for new drug development. The company generates revenue primarily by commercializing these in-licensed drugs in China and neighboring regions. Zai Lab has also expanded its revenue streams through co-development deals, wherein it collaborates with global pharmaceutical giants. This involves sharing research and development costs, thus reducing upfront investment while simultaneously broadening its pipeline. Furthermore, Zai Lab's financial success is bolstered by its strong market position in several key therapeutic areas, driving growth and reinforcing its status as a bridge between international drug innovation and the Chinese healthcare sector. With a focus on rapid commercialization and strong partnerships, Zai Lab continues to blaze a trail in the biopharma industry, well-suited for navigating both domestic and international markets.

Intrinsic Value
115.63 HKD
Undervaluation 87%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
62.5%
=
Gross Profit
267.2m
/
Revenue
427.8m
What is the Gross Margin of Zai Lab Ltd?

Based on Zai Lab Ltd's most recent financial statements, the company has Gross Margin of 62.5%.

Back to Top